You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
红日药业(300026.SZ)复方电解质注射液(Ⅱ)获药品注册批件
格隆汇 08-16 12:05

格隆汇8月16日丨红日药业(300026.SZ)宣布,公司于近日收到国家药品监督管理局下发的药品注册批件(批件号:2019S00462、2019S00463)。其中复方电解质注射液(Ⅱ)250ml规格,药品批准文号国药准字H20193223,有效期至2024年8月1日;复方电解质注射液(Ⅱ)500ml规格药品批准文号国药准字H20193224,有效期至2024年8月1。

该品种获批适应症为用于治疗伴随或预期出现酸中毒的等渗性脱水,补充细胞外液的丢失。目前公司已着手进行上市销售前的准备工作,由于医药产品具有高科技、高风险、高附加值的特点,药品投产后的未来市场销售情况可能受到市场环境变化、招投标开展等因素影响,存在不确定性

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account